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Abstract
Purpose: Acquired EGFR T790M mutations are the most
frequently identified resistance mechanism to EGFR tyro-
sine kinase inhibitors (TKI) in patients with EGFR-mutant
lung cancers. ASP8273 is a third-generation EGFR TKI
with antitumor activity in preclinical models of EGFR-
mutant lung cancer that targets mutant EGFR, including
EGFR T790M.
Experimental Design: In this multicohort, phase I study
(NCT02113813), escalating doses of ASP8273 (25–500 mg)
were administered once daily to non–small cell lung cancer
(NSCLC) patients with disease progression after prior treat-
ment with an EGFR TKI. EGFR T790M was required for all
cohorts, except the dose escalation cohort. Primary endpoints
were safety/tolerability; secondary endpoints were determi-
nation of the RP2D, pharmacokinetic profile, and prelimi-
nary antitumor activity of ASP8273. Evaluation of the use of
EGFR mutations in circulating free DNA (cfDNA) as a bio-
marker of ASP8273 treatment effects was an exploratory
endpoint.
Results:A total of110patientswere treatedwithASP8273across
dose escalation (n¼36), response–expansion (n¼36),RP2D(300
mg; n¼ 19) and food–effect (n¼ 19) cohorts. The most common
treatment-emergent adverse events included diarrhea, nausea,
fatigue, constipation, vomiting, and hyponatremia. Across all
doses, in patients with EGFR T790M, the response rate was
30.7% (n ¼ 27/88; 95% CI, 19.5%–44.5%), and median progres-
sion-free survival was 6.8 months (95% CI, 5.5–10.1 months).
EGFRmutations in cfDNA, both the activatingmutation and EGFR
T790M, became undetectable in most patients in the setting of
clinical response and reemerged upon disease progression.
Conclusions: ASP8273 was well tolerated and promoted
antitumor activity in patients with EGFR-mutant lung cancer
with disease progression on prior EGFR TKI therapy. Clin Cancer
Res; 23(24); 7467–73. 2017 AACR.
Introduction
Mutations in the EGFR gene result in constitutive activation of
EGFR signaling causing cell survival, proliferation, andmetastatic
spread (1–3). EGFR tyrosine kinase inhibitors (TKI) are the
recommended first-line treatment for EGFR-mutant lung cancers
with superior outcomes compared with standard cytotoxic che-
motherapy (4–6). The clinical activity of these agents is limited by
drug resistance most commonly due to acquisition of a second
EGFR mutation, EGFR T790M (7, 8). To overcome this mecha-
nism of resistance, mutant-selective, irreversible EGFR inhibitors
have been developed for patients with lung cancer after progres-
sion on an EGFR TKI with evidence of EGFR T790M (9).
Oncogenic mutations are typically identified in tumor tissue;
however, recent advances in technology have resulted in the
ability to perform "liquid biopsies" by assessing circulating free
tumor DNA (cfDNA) within plasma. These techniques identify
relevant genetic alterations from low levels of tumor-shed cfDNA
within plasma (10); concordance between cfDNA plasma assays
and tissue genotyping has been high (11–13). Limitations of
plasma assays include decreased sensitivity compared with tissue
testing, and results can be dependent on tumor volume and the
sites of disease (14). Similar to tissuemolecular genotyping, EGFR
mutations identified within plasma serve as biomarkers that
predict response to EGFR TKI treatment (12, 15, 16). Plasma
assays of EGFR exon 19 deletions (ex19del), EGFR L858R, and
T790M point mutations are now approved for clinical use (17).
Quantitative changes in the EGFR mutations may also have
predictive value. Failure to clear cfDNA-harboring EGFR muta-
tions predicts shorter response and inferior outcomes with
EGFR TKI treatment (15, 18). Similarly, a decline in the activating
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mutations and EGFR T790M occurs when treated with a third-
generation EGFR TKI and can begin to rise again with the emer-
gence of resistance (19).
ASP8273 is a small-molecule, irreversible, selective TKI that
inhibits the kinase activity of mutant EGFR, including EGFR
T790M. On the basis of preclinical activity, ASP8273 was evalu-
ated in two separate phase I/II studies in patients with EGFR-
mutant lung cancer in Japan and the United States; this article
details the final results of the ASP8273 phase I study conducted in
the United States.
Materials and Methods
Study oversight and design
This study was designed by the study sponsor in collaboration
with the investigators and was conducted in accordance with
the Declaration of Helsinki ethical principles, Good Clinical
Practices, principles of informed consent, and requirements of
public registration of clinical trials (ClinicalTrials.gov identifier,
NCT02113813). Site-specific Institutional Review Boards
approved the protocol. Written informed consent was obtained
from each subject at enrollment.
This prospective, open-label, multicenter dose escalation phase
I study was conducted across 10 sites in the United States and
consisted of dose escalation (25–500 mg), response–expansion
(100–400mg), recommendedphase II dose (RP2D; 300mg), and
food–effect (300 mg) cohorts (Supplementary Fig. S1). In the
dose-escalation cohorts, subjects at each dose level (25–500 mg)
were administered ASP8273 orally in a single-dose period (cycle
0; 2-day duration) followed by repeat-dose cycles consisting of
once-daily treatment over 21days (cycle 1 and subsequent cycles).
Bayesian continual reassessment method (CRM) was used to
guide the dose escalation or deescalation based on dose-limiting
toxicity (DLT) incidence. Dose levels continued to be escalated
using the dose escalation parameters until reaching the MTD
(defined as the highest dose level at which the posterior mean
DLT rate was <33%) or until establishing an RP2D dose. The
starting dose level was 25 mg/day, and escalation increments of
100%were used until one patient experienced a DLT or 2 patients
experienced a grade2 drug-related adverse event at a given dose
level during cycle 0 or 1. Thereafter, dose escalation increments
were approximately 50%.
As the dose escalation cohorts were ongoing, additional sub-
jects were enrolled in the response–expansion cohorts. The initial
response–expansion cohort was opened if a partial or complete
response at a dose level was observed or if pharmacokinetics data
were in the efficacious range based on preclinical models, pro-
viding the dose level was deemed tolerable. Once the first
response–expansion cohort was opened, each subsequent dose
level also enrolled a response–expansion cohort after the dose
level was cleared and deemed tolerable by the dose escalation
committee. Each response–expansion cohort could have up to
6 patients. Any DLTs identified during the DLT period in a
response–expansion cohort were included in the Bayesian CRM
model to determine dose escalation and the MTD. The RP2D of
ASP8273 was determined on the basis of consideration of safety,
pharmacokinetic profile, and antitumor activity and was not to
exceed the MTD.
Patients in the dose escalation cohorts who did not receive
80%of theplanneddoses ofASP8273during cycle 1, for reasons
other than treatment-related toxicity, were to be replaced and
observed for signs of toxicity; however, no patients were replaced.
Dose reductions were allowed in increments of 100 mg. Patients
who did not experience a DLT continued on treatment until
unacceptable toxicity, progression of disease, serious protocol
deviation, or withdrawal of informed consent.
The RP2D cohort consisted of approximately 15 patients to
assess ASP8273 antitumor activity and safety. Patients in the
food–effect cohort were randomized to receive a single dose of
the RP2D of ASP8273 at cycle 0 day 1 and cycle 0 day 4 under
assigned food conditions, followed by repeated daily dosing of
ASP8273 starting on cycle 1 day 1.
Patient selection
Patients had advanced (metastatic or unresectable) non–small
cell lung cancer (NSCLC) harboring an EGFR-sensitizing muta-
tion (e.g., ex19del, L858R) or an exon 20 insertion (ex20ins) and
previous EGFR TKI treatment; the patients in the response–
expansion, RP2D, and food–effect cohorts must have had an
EGFR T790M mutation. Patients could not have symptomatic
central nervous system metastases and could not require cortico-
steroid treatment. There was a 6-daywashout of EGFR TKI therapy
prior to study treatment initiation.
Endpoints and assessments
Theprimary endpointwas to assess the safety and tolerability of
ASP8273 and to determine the MTD and/or the RP2D of
ASP8273. Secondary endpoints included evaluating the antitu-
mor activity of ASP8273 and determining the ASP8273 pharma-
cokinetic profile; exploratory endpoints included evaluation of
potential biomarkers within cfDNA and tumor tissue.
During screening, patients underwent tumor imaging, including
an MRI brain scan if indicated; restaging scans were obtained at
6-week intervals during treatment and were assessed according to
theRECIST version 1.1. Adverse events (AE)were graded according
to theNationalCancer InstituteCommonTerminologyCriteria for
Adverse Events (NCI-CTCAE) version 4.0. A DLT was defined as
any grade 4 hematologic toxicity, grade 3 thrombocytopenia with
Translational Relevance
EGFR tyrosine kinase inhibitors (TKI) have shown clinical
activity in patients with non–small cell lung cancer (NSCLC)
harboring EGFR activationmutations; however, acquired resis-
tance often develops, limiting antitumor activity. ASP8273 is
an irreversible, once-daily, orally available TKI with activity
against both activating and resistance EGFR mutations. We
assessed the clinical pharmacology as well as safety/tolerability
and clinical response of ASP8273. In addition, utilizing cell-
free DNA assay, we were able to confirm inhibition and track
the emergence of drug resistance. ASP8273 was generally well
tolerated with a linear pharmacokinetic profile and a recom-
mended phase II dose of 300 mg. Patients with NSCLC har-
boring EGFR-T790M mutations had most pronounced antitu-
mor activity following treatment with ASP8273, which was
followed by variable reemergence of disease progression. As
EGFR T790M–mediated resistance to first- and second-gener-
ation EGFR TKIs is the dominant resistance mechanism iden-
tified to date, these data provide insight into thesemechanisms
and support the need for further studies.
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bleeding, or grade 3 febrile neutropenia. In addition, any grade3
nonhematologic AE was considered a DLT with the exception of:
(i) diarrhea, nausea, or vomiting that could be managed to grade
1 with supportive care; (ii) electrolyte abnormalities that did not
recur and could be managed to grade 1; or (iii) grade 3 alanine
transaminase/aspartate aminotransferase elevations that do not
recur after drug is held.
Plasma sampleswere serially collectedprior to study start and at
each treatment cycle. cfDNA was extracted from plasma samples
collected before and during treatment with ASP8273 and was
analyzed by beads, emulsification, amplification, and magnetics
(BEAMing) digital PCR for EGFR T790M, three coding variants of
EGFR exon 19 deletions (2235-49D, 2236-50D, and 2240-57D),
EGFR L858R, and EGFR C797S mutations. EGFRmutation status
was also assessed centrally by reverse-transcriptase PCR using
therascreen EGFR RGQ assay (Qiagen) in archival formalin-fixed,
paraffin-embedded tissue and plasma samples obtained prior to
treatment with ASP8273. EGFR mutation data were compared
with tumor response data for utility as pharmacodynamic bio-
marker and to explore resistance mechanisms to ASP8273; con-
cordance between tissue and plasma samples on EGFRmutation
status was also investigated. These samples were not paired;
archival tissue samples were collected any time after TKI failure,
and plasma samples were collected on the first day of cycle 1.
Blood samples were also collected to assess the pharmacoki-
netic profile of ASP8273. During dose escalation, blood samples
for pharmacokinetic analyses were collected for all subjects at
various time points over a 48-hour period in cycle 0 and a 24-hour
period in cycle 2. During response–expansion, blood samples for
pharmacokinetic analyses were collected for all subjects at various
time points over a 24-hour period on day 1 of cycles 1 and 2.
Statistical analysis
The sample size of the dose escalation cohortwas dependent on
the DLT incidence. The RP2D cohort sample size was based on
toxicity, antitumor activity, and pharmacokinetic data and was
based on a proposed response rate of 60%with a 95% confidence
interval (CI) of 32%–84%. All patients who received 1 dose of
study medication were included in the safety analysis set. Anti-
tumor activity data were summarized for all patients who had
both baseline and 1 postbaseline imaging assessment. Patients
who discontinued study participation for any reason before the
first radiographic assessment were counted as nonresponders.
Progression-free survival (PFS) was estimated using the
Kaplan–Meier method. The response rate was calculated using
binomial proportions and exact 95% CIs. Pharmacokinetic and
biomarker analyses were reported on all patients.
Results
FromApril 2014 toDecember 2015, 113patients were enrolled
at 10 centers in theUnited States; 110 patients received1 dose of
study drug across the dose escalation (n ¼ 36), response–expan-
sion (n ¼ 36), RP2D (n ¼ 19), and food–effect (n ¼ 19) cohorts.
The demographics and baseline disease characteristics of the 110
treated patients are listed in Table 1. All 110 patients dosed with
ASP8273 were evaluable for safety and efficacy. Twelve patients
did not have confirmed responses andwere therefore not counted
as responders. Of the 110 patients dosed with drug, only 93 had
detectable mutant EGFR cfDNA in plasma to provide data for
plasma/tissue concordance. Seventeen additional patients were
excluded from the plasma response analysis because their plasma
testing was negative, inadvertently not drawn, or not analyzed.
Only 46 patients had EGFR cfDNA detected and sufficient plasma
samples (>1) for longitudinal analysis.
Patients in the dose escalation cohorts received ASP8273 25 to
500mg; noDLTs were observed from 25 to 200mg. Four patients
experienced aDLT; one in the 300mgdose cohort and three in the
400 mg cohort: hyponatremia (n ¼ 2), anorexia (n ¼ 1), and
diarrhea (n ¼ 1). Although no patient in the 500 mg dose cohort
had a DLT, 6 of 7 patients required dose interruptions or mod-
ifications due to treatment-emergent grade 3 AEs. On the basis of
Bayesian CRM, the MTD was not reached, but the decision was
made not to further dose escalate based on the toxicities identified
Table 1. Baseline demographics and disease characteristics (FAS)
25 mg
(n ¼ 1)
50 mg
(n ¼ 2)
100 mg
(n ¼ 12)
200 mg
(n ¼ 12)
300 mg
(n ¼ 63)
400 mg
(n ¼ 13)
500 mg
(n ¼ 7)
Total
(n ¼ 110)
Median age, years (min, max) 82 (82, 82) 66 (55, 77) 68 (50, 85) 60 (38, 71) 64 (44, 81) 65 (55, 71) 64 (47, 72) 64 (38, 85)
Sex, n (%)
Male 0 1 (50) 4 (33) 1 (8) 16 (25) 6 (46) 2 (29) 30 (27)
Female 1 (100) 1 (50) 8 (67) 11 (92) 47 (75) 7 (54) 5 (71) 80 (73)
Race, n (%)
White 0 0 9 (75) 8 (67) 46 (73) 12 (92) 4 (57) 79 (72)
Black 0 0 1 (8) 1 (8) 6 (10) 1 (8) 0 9 (8)
Asian 1 (100) 2 (100) 2 (17) 2 (17) 9 (14) 0 2 (29) 18 (16)
Other 0 0 0 1 (8) 2 (3) 0 1 (14) 4 (4)
Prior EGFR TKI therapies for NSCLC, n (%)
Erlotinib 1 (100) 2 (100) 12 (100) 11 (92) 54 (86) 12 (92) 7 (100) 99 (90)
Afatinib 1 (100) 0 2 (17) 4 (33) 12 (19) 4 (31) 0 23 (21)
Gefitinib 0 0 0 0 2 (3) 0 0 2 (2)
EGFR mutation status by local testing, n (%)
Exon 19 deletion 0 1 (50) 8 (67) 9 (75) 33 (52) 8 (62) 3 (43) 62 (56)
Exon 21 L858R 1 (100) 1 (50) 4 (33) 2 (17) 15 (24) 3 (23) 2 (29) 28 (25)
Exon 18 G719x 0 0 0 0 4 (6) 0 0 4 (4)
Exon 20 insertion 0 0 0 0 1 (2) 1 (8) 0 2 (2)
T790M mutation status by local testing, n (%)
Positive 1 (100) 0 10 (83) 8 (67) 58 (92) 6 (46) 5 (71) 88 (80)
Negative 0 2 (100) 1 (8) 3 (25) 1 (2) 4 (31) 2 (29) 13 (12)
Unknown 0 0 1 (8) 1 (8) 4 (6) 3 (23) 0 9 (8)
Abbreviation: FAS, full analysis set.
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at the 500mgdose level. All but oneof the subjects tested forEGFR
mutations inplasmahadnear eliminationofEGFRT790McfDNA
in plasma by cycle 2 at all doses assessed (Supplementary Fig. S2).
On the basis of the aggregate safety, antitumor effect, and phar-
macokinetic data, the sponsor and study investigators set the
RP2D 300 mg once daily.
Analyses of plasma samples confirmed that ASP8273 showed a
linear pharmacokinetic profile and dose proportionality over
the dose range of 100 to 500 mg (Fig. 1; Supplementary Table
S1). Oral absorption was rapid with maximum concentrations
ranging from 1 to 4 hours; elimination half-life of ASP8273 was 6
to 14 hours. Steady-state ASP8273 concentration was achieved by
day 8 after once-daily dosing.
A total of 97% of patients (n ¼ 107/110) had 1 treatment-
emergent adverse event (TEAE); among these, 85% (n ¼ 93/110)
were considered treatment related. The most commonly reported
TEAEs were diarrhea (47%), nausea (42%), and fatigue
(32%; Table 2). Thirteen patients reported serious AEs that were
considered related to study treatment, while 40 patients (36%)
reported serious AEs not considered related to study drug. On the
basis of central electrocardiogram review, no patient had changes
from baseline QTcF values 60 msec or absolute QTcF values
>480msec. Ten patients died on study or during active follow-up,
none of which were considered related to treatment. Of the 110
ASP8273-treated patients, 17 required a dose reduction [100 mg
(n¼ 1), 300mg (n¼ 8), 400mg (n¼ 6), 500mg (n¼ 2)], and 22
patients discontinued study therapy following a TEAE.
All 110 patients treated with ASP8273 were evaluable for
response; antitumor activity was similar across dose levels of
ASP8273 (Fig. 2A). The majority of patients had a decrease in
the sum of their target lesions. At the time of data cutoff, February
10, 2016, 12 patients had disease assessments that were not
confirmed, and 8patients did not have scans. The overall response
rate (ORR) across all doses was 28.2% (n¼ 31/110; 95% CI, 20–
37.6); ORR at RP2Dwas 30.2% (n¼ 19/63; 95%CI, 19.2–43). In
all patients,median PFSwas 6months (95%CI, 4.5–7.2months);
median PFS was 6.8 months (95% CI, 5.5–10.1 months; Fig. 2B)
in the T790M-positive patients. In patients who harbored
an EGFR T790M mutation, the response rate was 31% (n ¼
18/58; 95% CI, 19.5–44.5). In patients who were EGFR T790M
negative, the response rate was 15.4% (n ¼ 2/13; 95% CI, 1.9–
45.4); median PFS for this population was 1.7 months (95% CI,
1.4–5.9 months).
Of the 110 patients enrolled, 93 (85%) with EGFR L858R or
ex19del mutations were eligible for biomarker analysis of cfDNA.
Mutant EGFR cfDNA was detectable in 1 plasma sample for 80
patients (86%); mutation concordance between cfDNA based on
BEAMing detection and local tissue testingwas 96% (95%CI, 80–
99), 67% (95% CI, 54–78), and 79% (95% CI, 68–86) for EGFR
L858R, ex19del, and T790M, respectively. Concordance between
cfDNA based on BEAMing detection and central tissue testing was
100% (95% CI, 74–100), 71% (95% CI, 54–83), and 84% (95%
CI, 69–92) for EGFR L858R, exon 19 deletion, and T790M,
respectively.
Of the 93 patients eligible, 46 had detectable EGFR cfDNA and
sufficient plasma samples for longitudinal analyses. In serially
monitored patients who achieved a partial response (PR) as best
overall response (n¼ 19/46, 41%) with ASP8273 (100–500mg),
treatment with ASP8273 consistently decreased EGFR activating
and T790M mutations in cfDNA to near or below the level of
detection after 1 cycle of treatment [<0.03% (ex19del/L858R);
<0.04% (T790M)], and levels generally remained undetectable
throughout the sustained PR. In serially monitored patients who
achieved stable disease (SD) as best overall response (n ¼
18/46, 39%), EGFR activating and T790M mutations in cfDNA
were generally reduced after 1 cycle of treatment; however,
variability was observed with stable or increased levels of EGFR-
activating mutations and T790M seen in some cases (Supple-
mentary Fig. S3).
Of the 9 serially monitored patients who developed acquired
resistance to ASP8273 (defined as progression after initial partial
responses) for whom cfDNA data are available, EGFR-activating
and T790M mutations reemerged in the plasma of 5 patients
(Supplementary Fig. S4). In two of these cases, activating and
T790M mutations decreased below detection during PR and
remained below the limit of detection despite clinical disease
progression. In one patient, T790M reemerged at the time of
disease progression while the original activating mutation
remained below the limit of detection; in another patient, the
original activating mutation reemerged at the time of disease
progression while T790M remained undetectable. BEAMing anal-
ysis for EGFR C797S was performed in a subset of 28 patients;
C797S was detectable in 3 patients, all of whom had progression
after initial PR. In those 3 patients, emergence of EGFR C797S
coincidedwith reemergence of EGFR T790Mand/or the activating
EGFR mutation.
Discussion
This phase I study suggests that ASP8273 is tolerable and
demonstrates antitumor activity in patients with EGFR T790M
who have progressed on a prior EGFR TKI inhibitor. Toxicities
seenwithASP8273 (e.g., diarrhea, nausea, and fatigue) are similar
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Figure 1.
Plasma concentration ofASP8273 in patients in the dose escalation cohorts after
a single dose of ASP8273. The figure illustrates plasma concentrations of
ASP8273 after a single dose over the subsequent 48 hours. Each colored line
represents the mean concentration of ASP8273 at each time point in
patients treated at a given dose level of ASP8273.
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to other drugs in class. Hyponatremia and paresthesias/neurop-
athymay occurmorewith ASP8273 comparedwith other drugs in
class; neuropathies were not reported in the osimertinib or
rociletinib phase I studies as drug-related AEs 10% (9, 20).
Hyponatremia is common in the metastatic lung cancer patient
population; however, in several cases, it was temporally consid-
ered related to drug initiation and resolved with discontinuation
of study drug, suggesting it is a unique toxicity seenwithASP8273.
ASP8273 demonstrated antitumor activity in patients with
EGFR-mutant lung cancers after prior treatment with EGFR TKIs.
This study identified the ASP8273 RP2D to be 300mg daily based
on pharmacokinetics, pharmacodynamics, safety, and antitumor
activity; theMTDwas not established. TheORRwas similar across
studied dose levels; ASP8273 had most pronounced activity in
patients with lung cancers harboring EGFR T790M, with a 31%
ORR in this population. Some patients with EGFR T790M–neg-
ative lung cancers appeared to have benefited: 15.4% (n ¼ 2/13)
of EGFR T790M–negative patients had a PR, and 23.1% (n ¼
3/13) had SD as their best response. In this initial phase I study,
theORR in patients with EGFR T790M–positive disease was lower
than the response rate seen in the phase I study of osimertinib, the
currently approved EGFR T790M inhibitor (9).
The ability to detect EGFR mutations in cfDNA is of significant
clinical importance. The recent approvals of plasmabased tests for
EGFR mutations in NSCLC demonstrate the novel clinical appli-
cation of these technologies. Furthermore, the ability to monitor
response and resistance to EGFR-targeted therapies constitutes an
important future use of these approaches. A unique aspect of
this study is the utilization of cfDNA as a biomarker to confirm
inhibition of the drug target, predict response to treatment, and
track emergence of drug resistance. Across all ASP8273 doses,
ASP8273 decreased circulating EGFR T790M cfDNA to below the
level of detection, confirming successful on-target inhibition.
The presence of EGFR T790M in cfDNA predicted response to
ASP8273 treatment and was highly correlated with the identifi-
cation of EGFR T790M in tumor tissue; ASP8273 response rate
was identical for patients who had EGFR T790M identified from
plasma versus tumor tissue. In patients who responded to
ASP8273, EGFR T790M and the EGFR-activatingmutation within
cfDNA were inhibited to undetectable levels that variably ree-
merged with disease progression. There were several patterns of
progression identified; somepatients had reemergence of both the
activating EGFRmutation and T790M cfDNA; some patients had
continued suppression of both mutations despite clinical
Table 2. Adverse events of ASP8273 (25–500 mg) occurring in 15% of all patients (FAS)
Event, n (%)
25 mg
(n ¼ 1)
50 mg
(n ¼ 2)
100 mg
(n ¼ 12)
200 mg
(n ¼ 12)
300 mg
(n ¼ 63)
400 mg
(n ¼ 13)
500 mg
(n ¼ 7)
Total
(n ¼ 110)
Diarrhea
Any grade 0 1 (50) 1 (8) 2 (17) 34 (54) 8 (62) 6 (86) 52 (47)
Grade 3 0 0 0 0 1 (2) 2 (15) 1 (14) 4 (4)
Nausea
Any grade 0 1 (50) 3 (25) 7 (58) 24 (38) 7 (54) 4 (57) 46 (42)
Grade 3 0 0 1 (8) 0 1 (2) 1 (8) 0 3 (3)
Fatigue
Any grade 0 0 4 (33) 3 (25) 14 (22) 10 (77) 4 (57) 35 (32)
Grade 3 0 0 0 1 (8) 1 (2) 1 (8) 0 3 (3)
Constipation
Any grade 0 1 (50) 2 (17) 4 (33) 15 (24) 6 (46) 4 (57) 32 (29)
Grade 3 0 0 0 0 1 (2) 1 (8) 0 2 (2)
Vomiting
Any grade 0 1 (50) 1 (8) 3 (25) 14 (22) 4 (31) 3 (43) 26 (24)
Grade 3 0 0 1 (8) 0 0 0 0 1 (1)
Hyponatremia
Any grade 0 0 3 (25) 3 (25) 13 (21) 2 (15) 4 (57) 25 (23)
Grade 3 0 0 3 (25) 2 (17) 8 (13) 2 (15) 4 (57) 19 (17)
Decreased appetite
Any grade 0 1 (50) 0 3 (25) 9 (14) 5 (38) 4 (57) 22 (20)
Grade 3 0 0 0 0 0 1 (8) 0 1 (1)
Dyspnea
Any grade 0 1 (50) 1 (8) 4 (33) 10 (16) 5 (38) 1 (14) 22 (20)
Grade 3 0 0 1 (8) 0 2 (3) 0 0 3 (3)
Headache
Any grade 0 0 2 (17) 5 (42) 11 (17) 2 (15) 2 (29) 22 (20)
Grade 3 0 0 0 1 (8) 0 0 0 1 (1)
Cough
Any grade 0 1 (50) 1 (8) 4 (33) 11 (17) 4 (31) 0 21 (19)
Grade 3 0 0 0 0 0 0 0 0
Dizziness
Any grade 0 0 1 (8) 4 (33) 14 (22) 1 (8) 1 (14) 21 (19)
Grade 3 0 0 0 0 1 (2) 0 0 1 (1)
Dry mouth
Any grade 0 0 0 2 (17) 9 (14) 4 (31) 3 (43) 18 (16)
Grade 3 0 0 0 0 0 0 0 0
Paresthesia
Any grade 0 0 0 1 (8) 12 (19) 5 (38) 0 18 (16)
Grade 3 0 0 0 0 0 0 0 0
Abbreviation: FAS, full analysis set.
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progression,while others had emergence of eitherEGFR T790Mor
activating EGFR mutation cfDNA. A few patients acquired an
EGFR C797S mutation in plasma, which has previously been
reported as a resistance mechanism in patients treated with
osimertinib (19, 21). Various limitations, however, exist that
must be addressed to further refine the use of these approaches
in both clinical research and clinical practice. In this study, our
ability to assess for novelmechanisms of resistance to ASP8273 in
cfDNA was limited by our use of a digital PCR assay focused on
recurring mutations in EGFR; further discovery efforts could
leverage evolving technologies for next-generation sequencing of
cfDNA (22). In addition, findings in this study demonstrate some
cases where decreases in EGFR cfDNA occurred in the absence of
observed reductions in tumor burden. Furthermore, in many
cases, the depth of tumor response is not well correlated with
EGFR cfDNA. Further research is needed to understand the asso-
ciation between cfDNA findings and mechanisms of resistance to
ASP8273 therapy. Similarly, a greater understanding of the rela-
tionship between cfDNA and tumor burden or other clinical
parameters will further enable the use of these technologies in
these novel applications.
EGFR T790M–mediated resistance to first- and second-gener-
ation EGFR TKIs is the dominant resistancemechanism identified
to date. Currently, osimertinib is the only drug approved for this
indication; in the published phase I study, osimertinib had a high
response rate and long median PFS on treatment (9). Compared
with osimertinib, ASP8273 appears to have less significant skin
toxicity (e.g., dry skin, rash, and pruritus). In addition, pneumo-
nitis has been observed with treatment with osimertinib and, to
date, there has not been a case of pneumonitis with ASP8273.
Furthermore, early data suggest that these T790M inhibitors may
be sequenced with additive benefit (23).
ASP8273, and the other third-generation EGFR TKIs, have
demonstrated activity in pretreated patients. Studies that assess
whether these agents are superior as an initial treatment option
for patients with EGFR-mutant lung cancers are warranted.
ASP8273 may have antitumor activity in patients with EGFR
T790M–negative disease, and further study will be required to
understand the appropriate population to treat with ASP8273.
The purpose of utilizing these agents in the first-line setting
would be to prevent EGFR T790M–mediated resistance from
developing.
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Figure 2.
A, Best percentage change in target
lesions. Waterfall plot for best percent
change in size of target lesions is
shown for all patients. The color key
indicates the daily dose of ASP8273.
The solid line at 30% represents
the boundary for determination of
partial response. B, Progression-free
survival. Kaplan–Meier estimates of
progression-free survival in patients
with EGFR T790M–positive,
metastatic non–small cell lung cancer
who received ASP8273 at doses of
25 to 500 mg orally daily; median
progression-free survival was 6.8
months (95% CI, 5.5–10.1).
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